Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

15.5K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.5K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

10.8K
10.8K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

2.0K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
2.0K
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

761
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
761
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Drug Discovery: Overview01:26

Drug Discovery: Overview

12.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thulium fiber laser versus Holmium laser enucleation of the prostate: 24-month outcomes from a prospective randomized non-inferiority trial.

World journal of urology·2026
Same author

Rates and Predictors of Persistent LUTS Medication Use After Laser Enucleation of the Prostate.

Lower urinary tract symptoms·2026
Same author

Robust Localization and Tracking of VRUs with Radar and Ultra-Wideband Sensors for Traffic Safety.

Sensors (Basel, Switzerland)·2026
Same author

Persistent structural alteration of the extended limbic system in adolescents with childhood maltreatment.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Lower urinary tract symptoms after laser enucleation of the prostate in patients with and without preoperative indwelling catheter.

International urology and nephrology·2025
Same author

Germany's national genomDE strategy.

Nature medicine·2025
Same journal

Conditional Immortalization of Human Cardiac Fibroblasts for Pro-Fibrotic and Anti-Fibrotic Drug Screening.

Frontiers in bioscience (Landmark edition)·2026
Same journal

NF-κB Involvement in Glaucoma-Associated Neuroinflammation: Focus on Glial Cells.

Frontiers in bioscience (Landmark edition)·2026
Same journal

Revealing the Molecular Network of Pattern-Triggered Immunity (PTI) Signal Transduction.

Frontiers in bioscience (Landmark edition)·2026
Same journal

Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.

Frontiers in bioscience (Landmark edition)·2026
Same journal

β-Ecdysterone Attenuates Ang II-Induced Senescence in Human Aortic Smooth Muscle Cells via Autophagy Activation and ROS Suppression Through AKT/mTOR Pathway Inhibition.

Frontiers in bioscience (Landmark edition)·2026
Same journal

Exploration of the Role of M2 Macrophages in Hepatocellular Carcinoma: Insights into Disulfidptosis and Cellular Interactions.

Frontiers in bioscience (Landmark edition)·2026
See all related articles

Related Experiment Video

Updated: Mar 12, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.6K

Binding kinetics in drug discovery - A current perspective.

Victoria Georgi1, Dorothee Andres1, Amaury E Fernandez-Montalvan1

  • 1Bayer Pharma AG, Lead Discovery Berlin, Muellerstrasse 178, 13353 Berlin, Germany.

Frontiers in Bioscience (Landmark Edition)
|November 5, 2016
PubMed
Summary
This summary is machine-generated.

Target binding kinetics (BK) significantly impacts drug performance. Understanding and optimizing BK, through structure-kinetic relationships (SKR), is crucial for prioritizing drug candidates in lead optimization.

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K
Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

21.6K

Related Experiment Videos

Last Updated: Mar 12, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.6K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K
Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

21.6K

Area of Science:

  • Drug discovery and development
  • Pharmacology
  • Medicinal chemistry

Background:

  • Target binding kinetics (BK) is debated for its role in therapeutic agent clinical performance.
  • Retrospective studies indicate BK differentiates marketed medicines, but its use in lead optimization is unclear.

Purpose of the Study:

  • To explore the understanding and rational optimization of binding kinetics (BK).
  • To review literature on structure-kinetic relationships (SKR) and their influencing factors.
  • To present a perspective on integrating BK into the drug discovery process.

Main Methods:

  • Literature review focusing on binding kinetics (BK) and structure-kinetic relationships (SKR).
  • Discussion of factors influencing SKR, including molecular flexibility and bonding interactions.
  • Overview of methodologies for investigating BK parameters.

Main Results:

  • Structure-kinetic relationships (SKR) are influenced by conformational changes, flexibility, hydrogen bonds, hydrophobicity, water, and covalent bonds.
  • Various methodologies exist for BK investigation, each with distinct advantages and limitations.
  • The integration of BK into drug discovery requires further consideration.

Conclusions:

  • Binding kinetics (BK) is a critical, yet underutilized, parameter in drug discovery.
  • Rational optimization of BK through understanding SKR can enhance lead prioritization.
  • Further research and integration of BK into drug discovery workflows are recommended.